207 related articles for article (PubMed ID: 20699437)
1. Androgen deprivation induces rapid involution and recovery of human prostate vasculature.
Godoy A; Montecinos VP; Gray DR; Sotomayor P; Yau JM; Vethanayagam RR; Singh S; Mohler JL; Smith GJ
Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E263-75. PubMed ID: 20699437
[TBL] [Abstract][Full Text] [Related]
2. Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma.
Montecinos VP; Godoy A; Hinklin J; Vethanayagam RR; Smith GJ
PLoS One; 2012; 7(1):e29623. PubMed ID: 22303438
[TBL] [Abstract][Full Text] [Related]
3. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
4. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.
Pallares J; Rojo F; Iriarte J; Morote J; Armadans LI; de Torres I
Histol Histopathol; 2006 Aug; 21(8):857-65. PubMed ID: 16691538
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.
Tesan T; Gustavsson H; Welén K; Damber JE
BJU Int; 2008 Sep; 102(8):1034-9. PubMed ID: 18489523
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma.
Häggström S; Bergh A; Damber JE
Prostate; 2000 Sep; 45(1):42-50. PubMed ID: 10960841
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and angiopoietin are required for prostate regeneration.
Wang GM; Kovalenko B; Huang Y; Moscatelli D
Prostate; 2007 Apr; 67(5):485-99. PubMed ID: 17221843
[TBL] [Abstract][Full Text] [Related]
9. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
11. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis.
Gray DR; Huss WJ; Yau JM; Durham LE; Werdin ES; Funkhouser WK; Smith GJ
Cancer Res; 2004 Mar; 64(5):1712-21. PubMed ID: 14996731
[TBL] [Abstract][Full Text] [Related]
12. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.
Zhou JR; Yu L; Zerbini LF; Libermann TA; Blackburn GL
Int J Cancer; 2004 Jul; 110(6):800-6. PubMed ID: 15170660
[TBL] [Abstract][Full Text] [Related]
13. The role of vascular endothelial growth factor in the tissue specific in vivo growth of prostate cancer cells.
Krupski T; Harding MA; Herce ME; Gulding KM; Stoler MH; Theodorescu D
Growth Factors; 2001; 18(4):287-302. PubMed ID: 11519827
[TBL] [Abstract][Full Text] [Related]
14. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.
Placencio VR; Sharif-Afshar AR; Li X; Huang H; Uwamariya C; Neilson EG; Shen MM; Matusik RJ; Hayward SW; Bhowmick NA
Cancer Res; 2008 Jun; 68(12):4709-18. PubMed ID: 18559517
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
16. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
Gao J; Arnold JT; Isaacs JT
Cancer Res; 2001 Jul; 61(13):5038-44. PubMed ID: 11431338
[TBL] [Abstract][Full Text] [Related]
17. Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer.
Häggström S; Stattin P; Wikström P; Bergh A; Damber JE
BJU Int; 2001 Jul; 88(1):110-6. PubMed ID: 11446858
[TBL] [Abstract][Full Text] [Related]
18. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas.
Doll JA; Stellmach VM; Bouck NP; Bergh AR; Lee C; Abramson LP; Cornwell ML; Pins MR; Borensztajn J; Crawford SE
Nat Med; 2003 Jun; 9(6):774-80. PubMed ID: 12740569
[TBL] [Abstract][Full Text] [Related]
19. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor.
Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP
Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
